You Position: Home > Paper
TREATMENT OF INTERFERON ALFA-2B COMBINED WITH LOW-DOSE CYTARABINE IN CHRONIC MYELOGENOUS LEUKEMIA
( views:216, downloads:16 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1009-9921.2004.01.006
- Key Word:
- 慢性髓细胞白血病;干扰素α-2b;低剂量阿糖胞苷;血液学;细胞遗传学
Abstract： 目的:探讨慢性髓细胞白血病(CML)患者使用干扰素α-2b(IFNα-2b)联合低剂量阿糖胞苷(LD Ara-C)治疗,其血液学和细胞遗传学的缓解率,寻找治疗CML的新途径.方法:采用IFNα-2b(300万U/d)+Ara-C(20mg·m2·d-1,每月用10 d)治疗CML慢性期(CP)患者30例,检测治疗后血液学缓解率和细胞遗传学缓解率,并与IFNα-2b+羟基脲(Hu)治疗组和单纯Hu治疗组作对照.结果:Hu+IFNα-2b+LD Ara-C治疗组治疗6个月的CHR率、总CHR率和Ph染色体阳性细胞下降病例百分数均显著高于IFNα-2b+Hu治疗组(P=0.004、P＜0.005和P=0.009)和单纯Hu治疗组(P=0.006、P＜0.005和P＜0.005),CML急变发生率低于单纯Hu治疗组(P＜0.005),而且发生急变的时间晚,5 a生存率明显高于IFNα-2b+Hu治疗组(P=0.014)和单纯Hu治疗组(P＜0.005).结论:CML(CP)患者采用IFN α-2b+LD Ara-C治疗可显著提高CML患者的CHR率,提高CML患者的细胞遗传学缓解率,延长CML患者的生存期.
- [1]Lewis JL,Davidson RJ,Grand FH,etc.Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.[J].1998,102(4).
- [2]P B, McGlave,X O, Shu,W, Wen,etc.Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program.[J].2000,95(7).
- [3].Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia.[J].1994,330(12).
- [4]Michallet M,Nicolini F,Guyotat D,etc.Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.[J].1997,337(4).
- [5]J E, Sokal,S S, Leong,G A, Gomez.Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia.[J].1987,59(1).
- [6]孙自敏,申雪英,潘理明,等.慢性粒细胞白血病变异型PH易位的研究[J].1992,(5).
- [7]张之南.血液病诊断及疗效标准[M].1998.